FDA wants yet more data on Takeda diabetes drug alogliptin

Article Date: 26/04/2012 10:00
FDA wants yet more data on Takeda diabetes drug alogliptin

Vacancy Search

Quick job search

Advanced Search

Latest News

Amag $1 billion deal to buy preterm birth drug Makena

Amag $1 billion deal to buy preterm birth drug Makena

NHS first with unique stem cell storage deal

NHS first with unique stem cell storage deal

Horizon is world leader in gene-editing with Sage buy

Horizon is world leader in gene-editing with Sage buy

NHS Innovation Challenge to focus on diabetes

NHS Innovation Challenge to focus on diabetes

Daiichi Sankyo set to acquire Ambit in $410 million deal

Daiichi Sankyo set to acquire Ambit in $410 million deal

Weekly Market Movers (to 26 Sep 2014)

EvaluatePharma’s EventAnalyzer delivers a weekly global round up of key events driving company valuations.

Esmo – Cleopatra survival data no poison for Roche’s Perjeta

Perjeta has given a most emphatic answer of “yes” to the one of the few questions left before it: Should it be the standard of care in first-line HER2-positive metastatic breast cancer? With...

Esmo – Missed Target leaves Endocyte clutching at straws

Followers of Endocyte had pinned their hopes on overall survival data from vintafolide’s phase II Target study providing definitive proof of efficacy. With results presented at the Esmo...

Fifteen medicines leap toward EU approval

Fifteen medicines leap toward EU approval

EMA involves individual patients in benefit/risk decisions

EMA involves individual patients in benefit/risk decisions
more news